Q&A

Presenter(s)

• 

  Christina V. Angeles, MD

  Assistant Professor of Surgery
  University of Michigan, Rogel Cancer Center
  Ann Arbor, Michigan, United States

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• 

  Joshua M.V Mammen, MD,PhD,MBA

  Professor and Chief of Surgical Oncology
  University of Nebraska
  Omaha, NE, United States

  Disclosure: United Healthcare (Individual(s) Involved: Self): Advisor or Review Panel member
• 

  John R. Hyngstrom, MD

  Associate Professor, Surgical Oncology
  Huntsman Cancer Institute, University of Utah Health
  Salt Lake City, Utah, United States

  Disclosure: Bristol Myers Squibb (Individual(s) Involved: Self): Consultant; Nektar Therapeutics (Individual(s) Involved: Self): Advisor or Review Panel member

Moderator(s)

• 

  Genevieve M. Boland, MD, PhD

  Section Head, Melanoma/Sarcoma Surgery
  Massachusetts General Hospital
  Boston, Massachusetts, United States

  Disclosure: Ankyra Therapeutics (Individual(s) Involved: Self): Stockholder; InterVenn Bioscience (Individual(s) Involved: Self): Research Grant or Support; Merck (Individual(s) Involved: Self): Advisor or Review Panel member; Nektar Therapeutics (Individual(s) Involved: Self): Advisor or Review Panel member; Novartis (Individual(s) Involved: Self): Advisor or Review Panel member; Olink Proteomics (Individual(s) Involved: Self): Research Grant or Support; Palleon Pharmaceuticals (Individual(s) Involved: Self): Research Grant or Support